Salt-Free Preparation of Trimethylsilyl Ethers
1.30–1.12 (m, 4 H), 1.09 (d, J = 6.2 Hz, 3 H), 0.98 (q, J = 12.0 Hz, box at room temperature for 2 h. The vial was transferred outside
2 H), 0.13 (s, 9 H) ppm. 13C NMR (126 MHz, C6D6): δ = 72.8, the glove box, and the solution was filtered through neutral alu-
45.9, 29.5, 28.9, 27.1, 26.8, 26.8, 21.3, 0.5 (3 C) ppm. GLC–MS
mina directly into an NMR tube. The filter cake was washed with
CD2Cl2, and the filtrate was immediately analyzed by NMR spec-
troscopy as well as by GLC and GLC–MS analysis, Ͼ95% yield
(NMR, Table 2). GLC: tR = 30.0 min. 1H NMR (500 MHz,
CD2Cl2): δ = 5.38–5.28 (m, 1 H), 3.48 (tt, J = 11.0, 4.7 Hz, 1 H),
2.25–2.21 (m, 1 H), 2.16 (ddd, J = 13.2, 5.1, 2.3 Hz, 1 H), 2.07–
1.94 (m, 2 H), 1.90–1.79 (m, 2 H), 1.75–1.67 (m, 1 H), 1.63–1.43
(m, 7 H), 1.44–1.33 (m, 3 H), 1.33–1.24 (m, 1 H), 1.24–1.04 (m, 10
H), 1.01 (s, 3 H), 0.93 (d, J = 6.5 Hz, 3 H), 0.88 (dd, J = 6.6,
2.0 Hz, 6 H), 0.70 (s, 3 H), 0.10 (s, 9 H) ppm. 13C NMR (126 MHz,
CD2Cl2): δ = 142.4, 122.2, 73.3, 57.8, 57.2, 51.3, 43.7, 43.3, 40.9,
40.5, 38.4, 37.2, 36.8, 33.1, 33.0, 32.9, 29.2, 29.0, 25.2, 24.8, 23.5,
23.3 (2 C), 22.1, 20.2, 19.5, 12.6, 0.9 (3 C) ppm. GLC–MS (EI):
m/z = 443.4 [M+ – CH3].
(EI): m/z = 185.1 [M+ – CH3].
Trimethyl[(trans-2-methylcyclohexyl)oxy]silane (3ag): Prepared
from trans-2-methylcyclohexanol (2g; 24.7 μL, 0.200 mmol,
1.00 equiv.) according to GP2, 75% yield (NMR, Table 2). GLC:
tR = 6.7 min. 1H NMR (500 MHz, C6D6): δ = 3.07 (td, J = 9.9,
4.2 Hz, 1 H), 1.89–1.80 (m, 1 H), 1.60 (ddd, J = 13.6, 7.9, 3.0 Hz,
2 H), 1.52–1.45 (m, 1 H), 1.46–1.29 (m, 2 H), 1.23–1.04 (m, 2 H),
1.02 (d, J = 6.5 Hz, 3 H), 0.95–0.81 (m, 1 H), 0.15 (s, 9 H) ppm.
13C NMR (126 MHz, C6D6): δ = 77.3, 40.6, 36.5, 33.9, 26.1, 25.5,
19.5, 0.6 (3 C) ppm. GLC–MS (EI): m/z = 186.1 [M+], 171.1 [M+
–
CH3].
Trimethyl[(1-phenylpropan-2-yl)oxy]silane[18a] (3ah): Prepared from
1-phenylpropan-2-ol (2h; 28.0 μL, 0.200 mmol, 1.00 equiv.) accord-
ing to GP2, 79% yield (NMR, Table 2). GLC: tR = 9.3 min. 1H
NMR (500 MHz, C6D6): δ = 7.20–7.13 (m, 2 H), 7.12–7.05 (m, 3
H), 3.92–3.79 (m, 1 H), 2.69 (dd, J = 13.1, 7.5 Hz, 1 H), 2.55 (dd,
J = 13.1, 5.2 Hz, 1 H), 1.11 (d, J = 6.0 Hz, 3 H), –0.03 (s, 9 H)
ppm. 13C NMR (126 MHz, C6D6): δ = 139.9, 130.0 (2 C), 128.3 (2
C), 126.3, 70.2, 46.8, 24.0, 0.0 (3 C) ppm. GLC–MS (EI): m/z =
193.1 [M+ – CH3].
Trimethyl(2-methyl-1-phenylpropan-2-yl)oxysilane (3ak): Prepared
from 2-methyl-1-phenylpropan-2-ol (2k; 30.9 μL, 0.200 mmol,
1.00 equiv.) according to GP2, Ͼ95% yield (NMR, Table 2). GLC:
tR = 10.3 min. 1H NMR (500 MHz, C6D6): δ = 7.23–7.08 (m, 5 H),
2.66 (s, 2 H), 1.14 (s, 6 H), 0.11 (s, 9 H) ppm. 13C NMR (126 MHz,
C6D6): δ = 139.1, 131.1 (2 C), 127.9 (2 C), 126.4, 74.3, 51.4, 29.8
(2 C), 2.7 (3 C) ppm. GLC–MS (EI): m/z = 207.1 [M+ – CH3].
(Benzyloxy)trimethylsilane[28] (3al): Prepared from benzyl alcohol
(2l; 20.7 μL, 0.200 mmol, 1.00 equiv.) according to GP2, 70% yield
{[(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl]oxy}trimethyl-
silane[26] (3ai): As (–)-menthol (2i) is a solid, we had to slightly
modify GP2 to perform the synthesis of 3ai. In a glove box,
B(C6F5)3 (2.6 mg, 5.0 μmol, 2.5 mol-%) was weighed into a 1.3 mL
GLC vial and dissolved in [D8]toluene (0.1 mL). Another 1.3 mL
GLC vial was charged with cyclohexa-2,5-dien-1-yltrimethylsilane
(1a; 33.5 mg, 0.220 mmol, 1.10 equiv.) and mesitylene (9.30 μL,
66.6 μmol, 33.3 mol-%, internal standard). After the addition of a
stir bar, the freshly prepared B(C6F5)3 solution was added, the vial
was capped, and the resulting solution was stirred for 1 h. (–)-Men-
thol (2i; 31.3 mg, 0.200 mmol, 1.00 equiv.) was dissolved in [D8]-
toluene (0.1 mL) in another vial. Outside the glove box, the
B(C6F5)3/1a solution was cooled to 0 °C by using an ice–water
bath, and the (–)-menthol solution was added by using a 250 μL
microsyringe through the septum cap, which resulted in vigorous
hydrogen evolution (pressure must be equalized on larger scale). The
end of the procedure was in accordance with GP2, 78% yield
1
(NMR, Table 2). GLC: tR = 8.0 min. H NMR (500 MHz, C6D6):
δ = 7.30 (d, J = 7.7 Hz, 2 H), 7.21–7.17 (m, 2 H), 7.13–7.07 (m, 1
H), 4.56 (s, 2 H), 0.10 (s, 9 H) ppm. 13C NMR (126 MHz, C6D6):
δ = 141.7, 128.5 (2 C), 127.3, 126.7 (2 C), 64.8, –0.3 (3 C) ppm.
GLC–MS (EI): m/z = 180.1 [M+], 165.1 [M+ – CH3], 91.1 [M+
–
OSi(CH3)3].
(4-Chlorophenoxy)trimethylsilane (3am): As 4-chlorophenol (2m) is
a solid, we had to slightly modify GP1 to perform the synthesis of
3am. In a glove box, B(C6F5)3 (2.6 mg, 5.0 μmol, 5.0 mol-%) was
weighed into a 1.3 mL GLC vial and dissolved in CD2Cl2 (0.1 mL).
Another 1.3 mL GLC vial was charged with cyclohexa-2,5-dien-1-
yltrimethylsilane (1a; 16.8 mg, 0.110 mmol, 1.10 equiv.) and mesity-
lene (4.6 μL, 33.3 μmol, 33.3 mol-%, internal standard). After the
addition of a stir bar, the freshly prepared B(C6F5)3 solution was
added, the vial was capped, and the resulting solution was stirred
for 30 min. 4-Chlorophenol (2m; 12.9 mg, 0.100 mmol, 1.00 equiv.)
was dissolved in CD2Cl2 (0.1 mL) in another vial. Outside the glove
box, the B(C6F5)3/1a solution was cooled to 0 °C by using an ice–
1
(NMR, Table 2). GLC: tR = 9.6 min. H NMR (500 MHz, C6D6):
δ = 3.41 (td, J = 10.2, 4.3 Hz, 1 H), 2.36 (dsept, J = 7.0, 2.2 Hz, 1
H), 1.99–1.89 (m, 1 H), 1.58–1.49 (m, 2 H), 1.29–1.20 (m, 2 H),
1.12 (q, J = 12.2, 11.7 Hz, 1 H), 0.95 (d, J = 7.1 Hz, 3 H), 0.87 (d, water bath, and the solution of 4-chlorophenol was added by using
J = 6.5 Hz, 3 H), 0.82 (d, J = 7.0 Hz, 3 H), 0.76 (qd, J = 14.1,
a 250 μL microsyringe through the septum cap, which resulted in
vigorous hydrogen evolution (pressure must be equalized on larger
13.1, 3.5 Hz, 1 H), 0.16 (s, 9 H) ppm; one proton overlapped with
the CH3 peaks. 13C NMR (126 MHz, C6D6): δ = 72.7, 50.6, 46.1, scale). The end of the procedure was in accordance with GP1, 76%
35.0, 31.9, 25.8, 23.4, 22.6, 21.5, 16.4, 0.8 (3 C) ppm. GLC–MS
yield (NMR, Table 2). GLC: tR = 9.2 min. 1H NMR (400 MHz,
C6D6): δ = 7.02 (d, J = 9.0 Hz, 2 H), 6.59 (d, J = 8.7 Hz, 2 H),
0.10 (s, 9 H) ppm. 13C NMR (126 MHz, C6D6): δ = 154.3, 129.8
(2 C), 126.8, 121.6 (2 C), 0.0 (3 C) ppm. GLC–MS (EI): m/z =
200.0 [M+], 185.0 [M+ – CH3].
(EI): m/z = 228.2 [M+], 213.2 [M+ – CH3].
(3β)-3-[(Trimethylsilyl)oxy]cholest-5-ene[27] (3aj): In a glove box,
B(C6F5)3 (1.3 mg, 2.5 μmol, 5.0 mol-%) was weighed into a 1.3 mL
GLC vial and dissolved in CD2Cl2 (0.2 mL). Another 1.3 mL GLC
vial was charged with cyclohexa-2,5-dien-1-yltrimethylsilane (1a;
8.4 mg, 55 μmol, 1.1 equiv.) and mesitylene (2.30 μL, 16.6 μmol,
33.3 mol-%, internal standard). After the addition of a stir bar, the
freshly prepared B(C6F5)3 solution was added, the vial was capped,
and the resulting solution was stirred for 30 min. Cholesterol (2j;
19.3 mg, 50.0 μmol, 1.00 equiv.) was dissolved in CD2Cl2 (0.3 mL)
in another vial. That solution was added by using a 250 μL micro-
syringe to the B(C6F5)3/1a solution, which resulted in vigorous hy-
drogen evolution (pressure must be equalized on larger scale). The
vial was capped, and the reaction mixture was stirred in a glove
Trimethyl[4-(trifluoromethyl)phenoxy]silane (3an): Prepared from 4-
(trifluoromethyl)phenol (2n; 16.2 mg, 0.100 mmol, 1.00 equiv.) ac-
cording to the modified GP1 described for the synthesis of 3am,
79% yield (NMR, Table 2). GLC: tR = 6.9 min. 1H NMR
(400 MHz, C6D6): δ = 7.31 (d, J = 8.4 Hz, 2 H), 6.68 (d, J = 7.0 Hz,
2 H), 0.11 (s, 9 H) ppm. 13C NMR (126 MHz, C6D6): δ = 158.5,
127.3 (q, J = 3.8 Hz, 2 C), 125.3 (q, J = 271.2 Hz), 123.9 (q, J =
32.8 Hz), 120.3 (2 C), 0.0 (3 C) ppm. 19F NMR (470 MHz, C6D6):
δ = –61.3 ppm. GLC–MS (EI): m/z = 234.1 [M+], 219.0 [M+
–
CH3].
Eur. J. Org. Chem. 2014, 2077–2083
© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjoc.org
2081